Ascendis Pharma A/S (ASND) Financial Statements
Ascendis Pharma A/S (ASND) reported trailing twelve-month revenue of $1.0B (up 113.4% year on year) and net income of $741.8M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: $335.1M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
ASNDAscendis Pharma A/SFollow ASND — free
—
Price chart with a free account
- Market cap
- 15.1B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 9 Nov, in 16 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.5 | 10.6 | 13.4 | 7.0 | 7.8 | 51.2 | 266.7 | 363.6 | 720.1 | 1,047.0 | |
| Gross profit | — | — | — | — | 4.3 | 39.0 | 222.3 | 319.4 | 625.2 | 955.9 | |
| Research & development | — | — | — | — | — | — | 413.5 | 307.0 | 303.6 | 280.0 | |
| Operating income | -111.5 | -154.8 | -226.7 | -330.6 | -451.8 | -561.8 | -455.5 | -278.8 | -136.3 | 266.2 | |
| Pre-tax income | -124.4 | -130.5 | -218.3 | -419.2 | -383.9 | -577.8 | -474.1 | -373.2 | -212.7 | 97.8 | |
| Income tax | -0.5 | -0.4 | -0.2 | -0.2 | -0.4 | 5.4 | 7.3 | 4.8 | 15.4 | -643.9 | |
| Net income | -123.9 | -130.1 | -218.0 | -419.0 | -383.6 | -583.2 | -481.4 | -378.1 | -228.0 | 741.8 | |
| Diluted EPS ($) | -3.68 | — | — | — | -7.00 | -10.40 | -8.55 | -6.53 | -3.76 | — | |
| Diluted shares (mn) | 33.6 | — | — | — | — | — | — | — | — | — |
USD millions · SEC XBRL
Ascendis Pharma A/S — questions
- What is Ascendis Pharma A/S's revenue?
- $1.0B over the twelve months to 2026-06-30, up 113.4% year on year, from its 10-Q and 10-K filings.
- What is Ascendis Pharma A/S's net income?
- $741.8M over the twelve months to 2026-06-30.
- What is Ascendis Pharma A/S's free cash flow?
- $335.1M over the twelve months to 2026-06-30.
Every figure on this page comes from Ascendis Pharma A/S's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.